Last updated: 15 June 2019 at 11:33pm EST

J Tyler Martin Net Worth




The estimated Net Worth of J Tyler Martin is at least 2.42 百万$ dollars as of 16 November 2012. J Martin owns over 35,759 units of Dynavax Technologies stock worth over 2,422,991$ and over the last 15 years J sold DVAX stock worth over 0$.

J Martin DVAX stock SEC Form 4 insiders trading

J has made over 1 trades of the Dynavax Technologies stock since 2012, according to the Form 4 filled with the SEC. Most recently J exercised 35,759 units of DVAX stock worth 56,499$ on 16 November 2012.

The largest trade J's ever made was exercising 35,759 units of Dynavax Technologies stock on 16 November 2012 worth over 56,499$. On average, J trades about 5,108 units every 0 days since 2010. As of 16 November 2012 J still owns at least 222,089 units of Dynavax Technologies stock.

You can see the complete history of J Martin stock trades at the bottom of the page.



What's J Martin's mailing address?

J's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY, CA, 94710.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over 196,839,440$ worth of Dynavax Technologies stock and bought 2,463,112 units worth 11,318,051$ . The most active insiders traders include Andrew A. F. HackPartners L P/Ilbiotechnolog...James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 1,533,390$. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth 43,127$.



What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.



Complete history of J Martin stock trades at Dynavax Technologies

インサイダー
取引
取引
合計金額
J Tyler Martin
VP Clinical Development、CMO
オプション行使 56,499$
16 Nov 2012


Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include: